DMAAFinancial Services · Shell CompaniesDMAA Stock Forecast: Drugs Made In America Acquisition Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 22 Aug 2026 — in the upper half.
DMAA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Drugs Made In America Acquisition Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
DMAA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DMAA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DMAA appears on the weeks it earns a place.
DMAA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Drugs Made In America Acquisition Corp. returned +4.6% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DMAA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Drugs Made In America Acquisition Corp. (DMAA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 59.7×
- Price / sales
- —
- Price / book
- 1.5×
- EV / EBITDA
- −128.3×
Cheaper than 12% of US stocks
Cheaper than 56% of US stocks
Cheaper than 97% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 57.1%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 77% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 2.6%
- Return on assets
- 2.5%
- Dividend yield
- —
Higher than 49% of US stocks
Higher than 62% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Drugs Made In America Acquisition Corp. (DMAA) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Drugs Made In America Acquisition Corp. has a market value of $261.0M and an enterprise value of $361.2M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: $6.7M.
Free cash flow in the twelve months to 31 Mar 2026: −$379K.
Trailing P/E: 59.7×.
Drugs Made In America Acquisition Corp. employs 0 people.
Data provided by Twelve Data
DMAA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| DMAADrugs Made In America Acquisition Corp. | $261.0M | 68 |
| TRGSTRG Latin America Acquisitions Corp. | $262.0M | 13 |
| OACCOaktree Acquisition Corp. III Life Sciences | $264.0M | 56 |
| VNMEVendome Acquisition Corp. I | $264.5M | 40 |
| RACRithm Acquisition Corp. | $256.5M | 52 |
| IPVVInterPrivate Investment Partners V, Inc. | $252.3M | 8 |
| DNMXDynamix Corp. III | $269.9M | 20 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Drugs Made In America Acquisition Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about DMAA stock
How does Ticker Nerd's model rank DMAA?
As at 22 Aug 2026, Drugs Made In America Acquisition Corp. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
What is the DMAA stock forecast for 2030?
No analyst covering Drugs Made In America Acquisition Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAA are extrapolating price history, which says nothing about the business.
How has DMAA stock performed over the past year?
Drugs Made In America Acquisition Corp. returned +4.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Drugs Made In America Acquisition Corp. do?
Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) established in 2024 and headquartered in Fort Lauderdale, Florida.
About Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) established in 2024 and headquartered in Fort Lauderdale, Florida. The company’s primary purpose is to facilitate a merger, share exchange, asset acquisition, or similar business combination with one or more businesses in the U.S. pharmaceutical sector. Emphasizing the importance of domestic pharmaceutical manufacturing, the firm actively seeks to identify and acquire revenue-generating businesses that can serve as the foundation for an "end-to-end" platform focused on producing drugs within the United States. By doing so, it aims to contribute to job creation, strengthen national security, and ensure a reliable domestic supply of affordable, high-quality medications. The company is guided by an experienced management and advisory team, including prominent industry leaders, leveraging deep sector relationships and expertise to achieve its objectives. In the broader financial market, Drugs Made In America Acquisition Corp. represents the growing trend of SPACs targeting healthcare innovation and supply chain resilience, positioning itself as a strategic player in the future landscape of U.S. pharmaceutical manufacturing.
CEO Ms. Lynn Stockwell · United States · https://dmaacorp.com